Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fresenius Kabi AG

Latest From Fresenius Kabi AG

Fresenius And Formycon Strike Stelara Settlement For Europe And Canada

Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.

Deals Biosimilars

Fresenius Divests Norwegian Plant To Prange

Fresenius Kabi has completed the divestment of a manufacturing plant in Halden, Norway, to Prange Group.

Manufacturing Deals

Fresenius Claims Edge With US Tocilizumab Biosimilar Approval

Fresenius Kabi has claimed an advantage in the biosimilar tocilizumab arena after its Tyenne rival to Actemra was approved by the US FDA in both intravenous and subcutaneous formulations.

Biosimilars Approvals

Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space

Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.

Executive Changes Leadership
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
  • Other Names / Subsidiaries
    • mAbxience S.L.